Scientific Presentations for Products in Development

Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.

To view Encore Presentations, visit our Encore Presentations Page.

Clinical and Molecular Characteristics of ARIEL3 Patients Who Derived Exceptional Benefit from Rucaparib Maintenance Treatment for High-Grade Ovarian Cancer (HGOC)

Poster Presentation 2021 ASCO Virtual Annual Meeting

Phase 1b/2 SEASTAR Trial: Safety, Pharmacokinetics, and Preliminary Efficacy of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Rucaparib and Angiogenesis Inhibitor Lucitanib in Patients with Advanced Solid Tumors

Poster Presentation 2021 ASCO Virtual Annual Meeting

Subgroup Analysis of Rucaparib Versus Chemotherapy as Treatment for BRCA-mutated, Advanced, Relapsed Ovarian Carcinoma: Effect of Platinum Sensitivity in the Randomized, Phase 3 Study ARIEL4

Poster Presentation 2021 ASCO Virtual Annual Meeting

LIO-1: Lucitanib + Nivolumab in Patients with Advanced Solid Tumors–Updated Phase 1b Results and Initial Experience in Phase 2 Ovarian Cancer Cohort (NCT04042116; ENGOT-GYN3/AGO/LIO)

Poster Presentation 2021 ASCO Virtual Annual Meeting

Evaluation of Rucaparib in Japanese Patients with a Previously Treated Advanced Solid Tumor

Poster Presentation 2021 AACR Virtual Annual Meeting

Genomic Characteristics and Response to Rucaparib and Enzalutamide in the Phase 1b RAMP Study of Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Poster Presentation 2021 AACR Virtual Annual Meeting

Rucaparib vs Chemotherapy in Patients With Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation: Efficacy and Safety From ARIEL4, a Randomized Phase 3 Study

Virtual Presentation 2021 SGO Virtual Meeting

Association of Co-Occurring Gene Alterations and Clinical Activity of Rucaparib in Patients With BRCA1- or BRCA2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Poster Presentation 2021 ASCO GU Virtual Meeting

Clinically Significant Events Associated With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treatments

Poster Presentation 2021 ASCO GU Virtual Meeting

Rucaparib + Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Pharmacokinetics (PK) and Safety Data From the Phase 1b RAMP Study

Poster Presentation 2021 ASCO GU Virtual Meeting

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Patients for Treatment With Rucaparib: Next-Generation Sequencing of Cell-free Tumor DNA (ctDNA) and Tumor Tissue

Poster Presentation 2020 SUO Virtual Meeting

Clinical Activity of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and <i>BRCA1</i> or <i>BRCA2</i> Mutations Identified by FoundationOne® Liquid CDx (F1L CDx)

Virtual Presentation 2020 PCF Scientific Retreat

Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: data from the phase 1b/2 LIO-1 study (CO-3810-101; NCT04042116)

Poster Presentation 2020 ESMO Virtual Meeting

LIO-1: A Phase 2 study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO)

Poster Presentation 2020 ESMO Virtual Meeting

Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase 3 ARIEL3 study

Poster Presentation 2020 ESMO Virtual Meeting

Rucaparib population pharmacokinetics and exposure-response analyses in patients with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Poster Presentation 2020 ESMO Virtual Meeting

Rucaparib + sacituzumab govitecan: initial data from the phase 1b/2 SEASTAR study (NCT03992131)

Poster Presentation 2020 ESMO Virtual Meeting

Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy to fibroblast activation protein alpha

Poster Presentation 2020 ESMO Virtual Meeting

Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either <i>BRCA1</i> or <i>BRCA2</i> Mutations

Virtual Presentation 2020 ICGS Digital Annual Global Meeting